Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Latest Financial Results
$21.M
Revenue for the three and six months ended June 30, 2025, was $13.7 million and $21.0 million respectively
$26.1M
As of June 30, 2025, Adaptimmune had cash and cash equivalents of $26.1 million and Total Liquidity1 of $26.1 million
1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2024
Report Links
For complete information regarding our financials, see our periodic filings